Background: Extranodal nasal-type NK (natural killer)/T-cell lymphoma in elderly patients is rare, and its prognosis is unclear. This study aims to investigate the clinical characteristics and prognosis of this lymphoma.
introduction
Extranodal nasal-type natural killer (NK)/T-cell lymphoma is an uncommon disease [1] [2] [3] [4] [5] [6] [7] . Patients with this lymphoma mainly present with destructive lesions in the nasal cavity and other regions in the upper respiratory system [8] [9] [10] . This disease also originates primarily in the extra-upper aerodigestive tract areas such as the skin, gastrointestinal tract, soft tissue, and testis [8] [9] [10] [11] . This entity is prevalent in young males and is often detected at an early stage; it is characterized by frequent angiocentricity and necrosis, Epstein-Barr virus infection, and propensity for extranodal dissemination [1] [2] [3] [4] 12] . Recent studies have revealed that patients with extranodal nasal-type NK/T-cell lymphoma in the nasal cavity, Waldeyer ring, and extra-upper aerodigestive system presented with different clinical features and prognosis [9-11, 13, 14] .
Patients with extranodal nasal-type NK/T-cell lymphoma respond well to radiotherapy, but they show intrinsic resistance to doxorubicin-based chemotherapy [1, 3, 4, 8, 15] . Owing to the high survival rate after primary radiotherapy and the low efficacy of initial chemotherapy, radiotherapy has recently been considered as a curative therapy modality for patients with early-stage disease [1-3, 13, 14, 16, 17] . Our previous studies have confirmed that primary radiotherapy resulted in a favorable outcome in both children and adults [1, 13, 14, 18] . In patients with aggressive lymphoma, age of >60 years has been identified as an important prognostic factor, and it has been incorporated into the international prognostic index (IPI) [19, 20] . There is substantial evidence that elderly patients with non-Hodgkin lymphoma (NHL) are likely to have comorbidities and receive less standard care for their disease, leading to high recurrence and mortality rates [21] . Although extranodal nasal-type NK/T-cell lymphoma is commonly diagnosed in young adults, it has rarely been diagnosed in the elderly patients [1, 10, 11] . The prognostic significance of old age is unknown in patients with extranodal nasal-type NK/Tcell lymphoma, and the treatment outcome of this subgroup has not been reported separately. There is insufficient data in the literature to explain this issue; therefore, we carried out an analysis of elderly patients with early-stage extranodal nasaltype NK/T-cell lymphoma of the upper aerodigestive system to determine the clinical presentation and treatment outcome of this rare geriatric malignancy.
original article patients and methods
patient population
We reviewed 27 patients with age >60 years who were newly diagnosed with extranodal nasal-type NK/T-cell lymphoma at the Cancer Hospital of Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China, from 1989 to 2008. All patients showed typical pathology and immunohistochemistry of extranodal nasal-type NK/T-cell lymphoma as described previously [13, 14, 18, 22] . Of the 27 patients, 3 with stages III and IV disease are excluded, and the remaining 24 with stages I and II disease formed the study population. All patients were staged according to the Ann Arbor system and were scored according to the stage-modified international prognostic index (mIPI). The prognostic factors in the mIPI assessments were used, as initially described by Shipp et al. [19] , except that the adverse risk factor for Ann Arbor stage was stage II disease but not stage III or IV disease. Initial clinical evaluation included complete history and physical examination; blood cell count; liver and renal function tests; serum lactate dehydrogenase (LDH) level; electrocardiogram; computed tomography and/or magnetic resonance imaging of the head and neck; computed tomography of the chest, abdomen, and pelvis; and bone marrow aspiration.
treatment
Radiotherapy was the primary treatment of early-stage extranodal nasaltype NK/T-cell lymphoma of the upper aerodigestive system at our institution [1, [12] [13] [14] 18] . Of the 24 patients, 23 received either radiotherapy alone (n = 15) or radiotherapy and chemotherapy (combined modality therapy, n = 8).
Among the patients receiving radiotherapy, 17 were treated with conventional radiation technique and 6 were treated with intensitymodulated radiation therapy or three-dimensional conformal radiotherapy. The clinical target volume, radiation techniques, and chemotherapeutic regimens have been previously described in detail [12, 13, 18] . The median radiation dose for primary tumor was 50 Gy (range: 45-56 Gy), and the dose per fraction was 1.8-2 Gy.
Nine patients received chemotherapy, including cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP), or CHOP-like regimen. The median number of chemotherapy cycles was 3, with a range of two to six cycles.
statistical analysis
Statistical analysis was carried out using follow-up data up to 30 June 2009. Tumor response evaluation and follow-up examination were carried out according to the previously reported guidelines [13, 23] . Cancer-specific survival (CSS), overall survival (OS), and progression-free survival (PFS) were estimated by the product-limit Kaplan-Meier method. CSS was defined as the period from the start of initial treatment until the time of lymphoma remission or until the last follow-up. OS was measured from the start of initial treatment until the time of patient death from any cause or until the last follow-up. PFS was measured from the start of initial treatment until the time of first local or distant progression, relapse, last follow-up, or death from any cause. The differences between survival curves were calculated by the log-rank test.
results

patient characteristics
Clinical characteristics of the 24 patients are listed in Table 1 . The study included 16 males and 8 females (male : female ratio, 2.0 : 1), with a median age of 65 years (range: 61-79 years). B symptoms were observed in only three patients (12.5%).
Cervical lymph nodes were detected in seven patients (29.2%), and LDH level was elevated in eight patients (33.3%). The majority of patients showed good performance and were grouped under the low or low-intermediate risk groups according to mIPI.
Primary tumor was located in the nasal cavity in 15 (62.5%) patients and in the Waldeyer ring in 9 (37.5%) patients. According to the Ann Arbor staging system, 17 (70.8%) patients had stage I disease and 7 (29.2%) had stage II disease.
comorbidity and mortality
Of the 24 patients, 11 (45.8%) had at least one comorbid disease. The most common comorbid diseases were cardiovascular diseases such as hypertension (n = 5) and coronary heart disease (n = 2), followed by chronic obstructive pulmonary disease (n = 3), hypothyroidism (n = 1), hyperthyroidism (n = 1), hepatitis B (n = 1), and diabetes (n = 1). Of these 11 patients, 3 (27.3%) had more than one comorbid disease. Seven patients had a history of pulmonary tuberculosis.
Thirteen patients had died at the last follow-up. Of these 13 patients, 8 (61.5%) died of lymphoma, 4 (30.8%) died of treatment-related mortality, and 1 (7.7%) died of an unknown cause. Of the four patients who died of treatment-related mortality, three died of severe chemotherapy-related complications: one patient died of neutropenia, one died of pulmonary infection, and one died of hepatic function failure. The remaining one patient died of cerebrovascular disease 15 days after the completion of radiotherapy.
response and survival
Response rates after treatment were evaluated for all the 24 patients. Of the 24 patients, 23 (95.8%) showed complete response (CR) to the treatment and 1 (4.2%) showed partial response.
The 5-year CSS, OS, and PFS rates for all the patients were 54.3%, 42.0%, and 40.2%, respectively (median follow-up time, 21.5 months; Figure 1 ). Owing to the small study population, univariate analysis revealed that none of the clinical characteristics such as sex, primary location of the tumor, B symptoms, performance status, Ann Arbor stage, cervical lymph node involvement, LDH level, and mIPI were prognostic factors for survival (Table 2) .
treatment outcome with therapy
We analyzed the survival rate of patients who underwent radiotherapy alone or those who underwent combined modality therapy. The CSS, OS, and PFS rates of the patients treated with radiotherapy alone were similar to those of patients treated with radiotherapy plus chemotherapy. The 5-year CSS rate of patients treated with radiotherapy alone was 43.5% (median, 41.8 months), while that of patients treated with radiotherapy and chemotherapy was 50% (median, 22.5 months) (P = 0.852). The corresponding OS and PFS rates of patients were 36.6% (median, 21.9 months) and 34.1% (median, 15.2 months) in the former treatment group and 50% (median, 22.5 months) and 50% (median, 15.9 months) in the latter treatment, respectively (P = 0.801 for OS, P = 0.694 for PFS) (Figure 2 ). One patient with stage II nasopharyngeal NK/ T-cell lymphoma who received chemotherapy alone died of the disease at 7 months.
patterns of failure
Of the 24 patients, 8 (33.3%) experienced relapse after treatment and no patient showed disease progression during the treatment period. Of these eight patients, seven developed multiple distant lymphatic and/or extranodal disseminations, of which one developed cervical lymph node recurrence as well. The remaining one patient developed local failure in the nasal cavity. The most common failure site was distant lymph node (n = 4), followed by skin (n = 2), bone marrow (n = 2), lung (n = 2), liver (n = 1), and spleen (n = 1).
discussion
Although the clinicopathologic features of extranodal nasaltype NK/T-cell lymphoma have been well recognized, there are very few data to describe the difference between the clinical presentations of the young and those of the elderly patients [10, 20] . The clinical features and treatment outcome are uncertain in elderly patients with extranodal nasal-type NK/T-cell lymphoma. To our knowledge, this is the first study to provide important data about these patients. Similar to the adults and children with extranodal nasal-type NK/T-cell lymphoma [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] , elderly patients with extranodal nasal-type NK/T-cell However, elderly patients are more likely to have comorbid diseases and treatment-related mortality and exhibit unfavorable prognosis. Furthermore, these patients showed similar survival rates irrespective of whether they were treated with radiotherapy alone or with combined modality therapy. Lymphoma is commonly observed in older patients, and >50% of NHL patients are aged >60 years [24] . Such patients show increasing incidence of NHL, and >60 years has been considered as an adverse prognostic factor [19, 21, 24, 25] . In many studies on elderly patients with lymphomas, old age was found to be significantly correlated with short disease-free survival time and OS time [20, [26] [27] [28] [29] . Consistent with these results, we found that elderly patients with extranodal nasaltype NK/T-cell lymphoma showed poor prognosis associated with high incidence of comorbid diseases and treatment-related mortality. Many patients (45.8%) in our study had at least 1 comorbid disease. Moreover, three patients died of chemotherapy-related complications and one patient died of a concomitant disease after the completion of radiotherapy. The treatment outcome for elderly patients was poor in terms of CSS, OS, and PFS rates. The 5-year OS and PFS rates were <50% for early-stage extranodal nasal-type NK/T-cell lymphoma patients. The high mortality rate during chemotherapy and radiotherapy may be a factor responsible for the poor prognosis of elderly patients with extranodal nasaltype NK/T-cell lymphoma. Numerous studies have reported that the use of doxorubicin-containing regimens was associated with a high risk of severe hematologic toxic effects in elderly cancer patients [30] [31] [32] [33] . Fatal infection and acute treatmentrelated events during chemotherapy were also more common in elderly patients with lymphomas [20, [26] [27] [28] . These acute treatment-related toxic effects and mortality may be associated with diminished organ functions and alterations in the distribution and metabolism of drugs in elderly patients [34] [35] [36] .
Radiotherapy should be the preferred treatment of localized extranodal nasal-type NK/T-cell lymphoma. The treatment outcomes of patients with extranodal nasal-type NK/T-cell lymphoma from literature are summarized in Table 3 . Several large studies have indicated that compared with the outcome of chemotherapy alone or initial chemotherapy, that of primary or upfront radiotherapy was favorable in adult patients [1-5, 10, 15, 37] . Extranodal nasal-type NK/T-cell lymphoma is resistant to conventional chemotherapy, and it usually shows a low CR rate of <40% and a high stable or progression disease rate of 40%-51% [1, 4, 8, 11, 15, 17, 38] . Owing to the low efficacy of conventional chemotherapy, adding CHOP-based chemotherapy to radiotherapy did not provide further survival benefit to early-stage extranodal nasal-type NK/T-cell lymphoma patients (Table 3) ; on the other hand, patients in the advanced stage of lymphoma treated with primary chemotherapy showed an extremely poor prognosis [1, 8, 11, 17, 39, 40] . Our previous studies have revealed that adults and children diagnosed with early-stage nasal and Waldeyer ring NK/T-cell lymphoma can achieve a favorable prognosis with primary radiotherapy [1, 13, 14, 18] . The 5-year OS and PFS rates for these patients were 71%-77% and 57%-72%, respectively. Consistent with other studies [2-4, 10, 17, 37-39] , the addition of chemotherapy to radiotherapy did not improve the survival of patients with early-stage nasal NK/T-cell lymphoma compared with those who received radiotherapy alone [1, 14] . Additionally, our previous studies have found that patients with early-stage Waldeyer ring NK/T-cell lymphoma may benefit from a combination of radiotherapy and chemotherapy [13, 14] . Recently, two phase I/II trials from Korea and Japan have investigated the efficacy of combined concurrent radiotherapy with new chemotherapeutic regimens in young patients [41, 42] . In the elderly population, impaired vascularity and insufficiencies in the functions of important organs are common findings [43] [44] [45] [46] . Whether elderly patients with extranodal nasal-type NK/T-cell lymphoma can tolerate chemotherapy and radiotherapy and benefit from curative-intent radiotherapy is still a topic of concern. The results of our study clearly showed that a vast majority of elderly patients can achieve high overall response rate after treatment. However, this high initial response rate was not translated into good long-term survival in terms of OS or PFS. The prognosis of elderly patients was markedly poorer than that of adults and children [1, [13] [14] [15] 18] . Consistent with the results of previous studies on adult patients [1, 16, 17] , we confirmed that the survival in patients treated with radiotherapy alone was similar to that in patients treated with combined modality therapy, in this small cohort of elderly patients with early-stage extranodal nasal-type NK/T-cell lymphoma. The limited number of patients and the retrospective nature of our study reduced the reliability of our results. It was difficult to make a definite conclusion about the optimal treatment of elderly patients with extranodal nasal-type NK/Tcell lymphoma. However, it should be considered that elderly patients have usually been excluded from most clinical trials, and there are few state-of-the-art treatment recommendations for these patients [21] . When assessing the treatment options for elderly patients, we should pay great attention to age-related factors, especially diminished organ functions and comorbid diseases. Considering the high risk of treatment-related mortality, the use of any treatment, especially chemotherapy, in elderly patients with extranodal nasal-type NK/T-cell lymphoma requires strict evaluation of patient comorbidity, performance status, and functions of important organs. Multicenter clinical trials investigating the efficacy and feasibility of innovative treatment strategies or chemotherapeutic regimens in these patients are warranted.
The results of univariate analysis revealed that the clinical characteristics had no prognostic value for survival. This is probably because of the small number of patients included in this study. Previous studies have demonstrated that the location of the primary tumor, extension of primary tumor, B symptoms, elevated LDH levels, tumor stage, and IPI were the prognostic factors for survival in adult patients with extranodal nasal-type NK/T-cell lymphoma [1, 3, 10, [12] [13] [14] [15] 47] .
In conclusion, the findings of our study provide valuable data on clinical features and treatment outcomes in elderly patients 
